Moderna Begins Phase 3 Of Its COVID-19 Vaccine Trial

The video discusses a trial for Moderna's experimental mRNA COVID-19 vaccine, involving 30,000 volunteers. Unlike traditional vaccines, it uses mRNA to trigger an immune response. Participants receive either the vaccine or a placebo, and researchers monitor them for COVID-19 infections. Moderna aims to produce up to 1 billion doses by 2021, with potential protection lasting up to two years.

What is the unique feature of Moderna's vaccine compared to traditional vaccines?

• It uses a live virus.

• It introduces a small amount of virus.

• It is administered orally.

• It uses mRNA to trigger an immune response.

What is the purpose of giving some participants a placebo in the vaccine trial?

• To test the placebo effect.

• To compare the infection rates between the placebo and vaccine groups.

• To ensure all participants receive some form of treatment.

• To reduce the cost of the trial.

How will researchers determine the effectiveness of the vaccine?

• By observing the side effects in participants.

• By comparing the vaccine to other vaccines.

• By measuring the immune response in a lab.

• By tracking the number of COVID-19 infections in the trial groups.

What is Moderna's production goal for the vaccine by 2021?

• 500 million doses

• 1 billion doses

• 2 billion doses

• 750 million doses

For how long could the vaccine potentially protect against the coronavirus?

• Five years

• Two years

• One year

• Six months